CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 224 enrolled
Drug / intervention
Iomeronother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02596048
NCT02596048Phase 4Completed
CompareCT.gov

A Phase IV Multicenter Study of Iomeron®-400 Used With Multi-detector Computed Tomography Angiography (MDCTA) of the Thoraco-Abdominal Aorta, and the Carotid, Pulmonary, and Peripheral Arteries

Bracco Diagnostics, Inc·interventional·Posted Nov 4, 2015·Updated Jun 2, 2017

In Brief

A Phase 4 clinical trial evaluating Iomeron for Aortic Disorders and 3 related conditions. Completed, enrolled 224 participants across 5 sites.

Detailed Summary

This is a Phase IV multicenter, open-label study and is being implemented in order to assess diagnostic image quality of MDCTA in subjects undergoing computed tomography angiography (CTA) of the thoraco-abdominal aorta, and the carotid, pulmonary and peripheral arteries with IOMERON.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Disorders, Carotid Disease, Pulmonary Disease, Peripheral Artery Disease
CountriesChina
CollaboratorsBracco International B.V., Clinipace Worldwide

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 4, 2015
Enrollment StartDec 1, 2015
Primary CompletionApr 30, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.7 years ago

Interventions

Iomeronother

Iomeron or Imeron which is a iomeprol injection, hereafter referred to as iomeprol is an injectable solution of iomeprol, a non-ionic hydrosoluble iodinated compound used as a medical imaging contrast agent for radiological examinations.